全文获取类型
收费全文 | 180808篇 |
免费 | 1231篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 1208篇 |
儿科学 | 6776篇 |
妇产科学 | 3127篇 |
基础医学 | 17381篇 |
口腔科学 | 1678篇 |
临床医学 | 12731篇 |
内科学 | 32113篇 |
皮肤病学 | 928篇 |
神经病学 | 16911篇 |
特种医学 | 9025篇 |
外科学 | 29217篇 |
综合类 | 2333篇 |
预防医学 | 18279篇 |
眼科学 | 2862篇 |
药学 | 9914篇 |
中国医学 | 647篇 |
肿瘤学 | 16948篇 |
出版年
2023年 | 46篇 |
2022年 | 37篇 |
2021年 | 162篇 |
2020年 | 106篇 |
2019年 | 199篇 |
2018年 | 22072篇 |
2017年 | 17467篇 |
2016年 | 19639篇 |
2015年 | 1059篇 |
2014年 | 1007篇 |
2013年 | 1022篇 |
2012年 | 7374篇 |
2011年 | 21392篇 |
2010年 | 19038篇 |
2009年 | 11712篇 |
2008年 | 19809篇 |
2007年 | 22061篇 |
2006年 | 939篇 |
2005年 | 2574篇 |
2004年 | 3743篇 |
2003年 | 4654篇 |
2002年 | 2828篇 |
2001年 | 337篇 |
2000年 | 445篇 |
1999年 | 211篇 |
1998年 | 251篇 |
1997年 | 242篇 |
1996年 | 128篇 |
1995年 | 132篇 |
1994年 | 134篇 |
1993年 | 88篇 |
1992年 | 56篇 |
1991年 | 103篇 |
1990年 | 138篇 |
1989年 | 87篇 |
1988年 | 65篇 |
1987年 | 46篇 |
1986年 | 29篇 |
1985年 | 33篇 |
1982年 | 36篇 |
1980年 | 43篇 |
1974年 | 25篇 |
1970年 | 22篇 |
1969年 | 23篇 |
1938年 | 60篇 |
1937年 | 25篇 |
1935年 | 22篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
Iwasa-Inoue Naomi Nomura Hiroyuki Kataoka Fumio Chiyoda Tatsuyuki Yoshihama Tomoko Nanki Yoshiko Sakai Kensuke Kobayashi Yusuke Yamagami Wataru Morisada Tohru Hirasawa Akira Aoki Daisuke 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(2):441-447
International Journal of Clinical Oncology - This study aimed to investigate the clinical benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian,... 相似文献
2.
Kensuke Kudou Hiroshi Saeki Yuichiro Nakashima Shun Sasaki Tomoko Jogo Kosuke Hirose Qingjiang Hu Yasuo Tsuda Koichi Kimura Ryota Nakanishi Nobuhide Kubo Koji Ando Eiji Oki Tetsuo Ikeda Yoshihiko Maehara 《American journal of surgery》2019,217(4):757-763
Background
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).Methods
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.Results
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P?=?0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P?=?0.0237).Conclusions
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC. 相似文献3.
4.
5.
Eo Toriyama Tomoko Hata Kenichi Yokota Masahiko Chiwata Rena Kamijo Miki Hashimoto Masataka Taguchi Makiko Horai Masatoshi Matsuo Emi Matsuo Yumi Takasaki Yasuhisa Kawaguchi Hidehiro Itonaga Shinya Sato Koji Ando Yasushi Sawayama Jun Taguchi Yoshitaka Imaizumi Hideki Tsushima Tatsuro Jo Shinichiro Yoshida Yukiyoshi Moriuchi Yasushi Miyazaki 《Cancer science》2020,111(12):4490
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients. 相似文献
6.
Huinan Zhang Jingru Meng Shimeng Zhou Yunhan Liu Di Qu Ling Wang Xubo Li Ning Wang Xiaoxing Luo Xue Ma 《The AAPS journal》2016,18(2):385-394
Exendin-4 is now considered as a promising drug for the treatment of cerebral ischemia. To determine the neuroprotective effects of intranasal exendin-4, C57BL/6J mice were intranasally administered with exendin-4 daily for 7 days before middle cerebral artery occlusion (MCAO) surgery. Intranasally administered exendin-4 produced higher brain concentrations and lower plasma concentrations when compared to identical doses administered interperitoneally. Neurological deficits and volume of infarcted lesions were analyzed 24 h after ischemia. Intranasal administration of exendin-4 exhibited significant neuroprotection in C57BL/6 mice subjected to MCAO by reducing neurological deficit scores and infarct volume. The neuroprotective effects of exendin-4 were blocked by the knockdown of GLP-1R with shRNA. However, exendin-4 has no impact on glucose and insulin levels which indicated that the neuroprotective effect was mediated by the activation of GLP-1R in the brain. Exendin-4 intranasal administration restored the balance between pro- and anti-apoptotic proteins and decreased the expression of Caspase-3. The anti-apoptotic effect was mediated by the cAMP/PKA and PI3K/Akt pathway. These findings provided evidence that exendin-4 intranasal administration exerted a neuroprotective effect mediated by an anti-apoptotic mechanism in MCAO mice and protected neurons against ischemic injury through the GLP-1R pathway in the brain. Intranasal delivery of exendin-4 might be a promising strategy for the treatment of ischemic stroke. 相似文献
7.
8.
9.
Khushbu K. Modi Suresh B. Rangasamy Sridevi Dasarathi Avik Roy Kalipada Pahan 《Journal of neuroimmune pharmacology》2016,11(4):693-707
This study underlines the importance of cinnamon, a commonly used natural spice and flavoring material, and its metabolite sodium benzoate (NaB) in converting poor learning mice to good learning ones. NaB, but not sodium formate, was found to upregulate plasticity-related molecules, stimulate NMDA- and AMPA-sensitive calcium influx and increase of spine density in cultured hippocampal neurons. NaB induced the activation of CREB in hippocampal neurons via protein kinase A (PKA), which was responsible for the upregulation of plasticity-related molecules. Finally, spatial memory consolidation-induced activation of CREB and expression of different plasticity-related molecules were less in the hippocampus of poor learning mice as compared to good learning ones. However, oral treatment of cinnamon and NaB increased spatial memory consolidation-induced activation of CREB and expression of plasticity-related molecules in the hippocampus of poor-learning mice and converted poor learners into good learners. These results describe a novel property of cinnamon in switching poor learners to good learners via stimulating hippocampal plasticity. 相似文献
10.
Savleen Kaur Sonam Yangzes Swati Singh Nishant Sachdev 《International ophthalmology》2016,36(3):335-340
To evaluate the efficacy and safety of treatment of diabetic macular edema (persistent type) with difluprednate ophthalmic emulsion 0.05 % (off label use). 20 patients with persistent diabetic macular edema were enrolled. In all subjects, more than 4 months had passed since prior treatment. All patients were treated with difluprednate ophthalmic emulsion 0.05 % three times daily for 3 months. At the end of 3 months the visual acuity had increased by two lines to a mean value of 0.61 ± 0.18 on logMAR from a baseline value of 0.885 ± 0.20 and the central retinal thickness had decreased from 423 ± 72.04 microns to 345 ± 68.7 microns. Hence, there was a total of 18.4 % decrease in retinal thickness on difluprednate. Major side effects included raised intraocular pressure in 20 %. Difluprednate is a potent and strong steroid which causes a rapid decrease in persistent diabetic macular edema. However, the potential side effect of raised intraocular pressure limits its use as an adjuvant therapy in non-steroid responders. 相似文献